Barclays’s Curanex Pharmaceuticals CURX Stock Holding History

Barclays’s Portfolio CURX Stock Details CURX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,594	Closed	-$3.31K	–	5840
2025 Q3	$3.31K	Buy	+4,594	New	+$20.8K	﹤0.01%	5115

Other funds holding CURX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Barclays's CURX Position: Q4 2025 in Review

Barclays sold out of Curanex Pharmaceuticals (CURX) in Q4 2025, closing a stake of 4,594 shares — an estimated $3.31K sold.

Barclays first reported a position in CURX in Q3 2025 and held it in 1 quarter. The position peaked at $3.31K in Q3 2025. 11 funds tracked by Wall St. Rank hold CURX as of Q4 2025.

Barclays reported no remaining Curanex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Barclays sold 4,594 Curanex Pharmaceuticals shares in Q4 2025, an estimated $3.31K.
Barclays first reported a position in Curanex Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Barclays's Curanex Pharmaceuticals position peaked at $3.31K in Q3 2025.
11 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.